VolitionRx Limited (VNRX) Fair Value 2026

VNRX · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, VolitionRx Limited (VNRX) trades at $0.50. QOC: 5.7/10. Value Trap Risk: 26/100 (LOW). 1/13 models active.

Key Facts

Ticker
VNRX
Price
$0.50
Quality Score
5.7/10
Value Trap Risk
26/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give VNRX?

1 Intrinsic Value Models vs. Current Price ($0.50)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.48 -5.1%

All Models Active

All 1 models are displayed above.

What Is VolitionRx Limited (VNRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, VolitionRx Limited's intrinsic value is estimated at $0.48. Trading at its current price of $0.50, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -5.1%.

What Do the Models Say About VNRX?

1 of 13 models are currently active for VNRX. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does VNRX Rank in Medical Devices?

Among 157 Medical Devices stocks, VNRX ranks #100 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to healthcare company businesses. For VolitionRx Limited, metrics like R&D productivity ratio provide important context that general-purpose valuation models may underweight.

Is VNRX a Value Trap?

CirclFi's Value Trap algorithm assigns VNRX a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for VolitionRx Limited. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, VolitionRx Limited scores 5.7 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every VNRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across VNRX's 1 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy VolitionRx Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

CVCapsoVision, Inc.QOC 5.7TLSITriSalus Life Sciences, Inc.QOC 5.7CODXCo-Diagnostics, Inc.QOC 5.8BMRABiomerica, Inc.QOC 5.7ADMTADM Tronics Unlimited, Inc.QOC 5.8SINTSintx Technologies, Inc.QOC 5.7ADGMAdagio Medical Holdings, Inc.QOC 4.3HAEHaemonetics CorporationQOC 8.3GKOSGlaukos CorporationQOC 6.7IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: CV · TLSI · CODX · BMRA · ADMT · SINT · ADGM · HAE · GKOS · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to VNRX?

7 companies across all industries closest to VNRX’s Quality of Company score of 5.7/10.

NNBRNN, Inc.QOC 5.7CAHOCaro Holdings Inc.QOC 5.7ASTIAscent Solar Technologies, IncQOC 5.7EFOIEnergy Focus, Inc.QOC 5.7FCHLFitness Champs Holdings LimitedQOC 5.7CRWVCoreWeave, Inc.QOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NNBR · CAHO · ASTI · EFOI · FCHL · CRWV · NVDA

Where Does VNRX Sit in CirclFi's Medical Devices Rankings?

VNRX is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About VolitionRx Limited’s Valuation?

What is VolitionRx Limited's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for VolitionRx Limited (VNRX). The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is VNRX overvalued or undervalued right now?

At $0.50, 0 of 1 active models suggest VNRX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits VolitionRx Limited's business model in Medical Devices.

What does a Quality of Company score of 5.7 mean for VNRX?

VolitionRx Limited's QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on VNRX?

CirclFi analyzes VNRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is VNRX a value trap in 2026?

VolitionRx Limited's Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns VolitionRx Limited (VNRX) a Quality of Company score of 5.7/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/VNRX/ · Methodology
Primary sources for this VNRX valuation
  • Financial statements: VolitionRx Limited 10-K and 10-Q filings on SEC EDGAR (CIK 0000093314) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for VNRX as of ; valuations recomputed .